Cargando…
A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer
Purpose: Pre-operative chemoradiation (CRT) is currently the standard of care for patients with clinical stage II and III rectal cancer but only about 45% of patients achieve tumor downstaging and <20% of patients achieve a pathologic complete response. Better methods to stratify patients accordi...
Autores principales: | Chan, Jason, Kinsella, Michael T., Willis, Joseph E., Hu, Huankai, Reynolds, Harry, Delaney, Conor, McCulla, Andrea, Deharo, Steve, Ahdesmäki, Miika, Allen, Wendy Louise, Johnston, Patrick G., Kinsella, Timothy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839295/ https://www.ncbi.nlm.nih.gov/pubmed/24324931 http://dx.doi.org/10.3389/fonc.2013.00288 |
Ejemplares similares
-
Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021) -
Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015) -
Neoadjuvant chemoradiation for rectal cancer in patients aged 75 years or older
por: Lombardi, Raffaele, et al.
Publicado: (2009) -
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
por: Restivo, Angelo, et al.
Publicado: (2015) -
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
por: Dayde, Delphine, et al.
Publicado: (2017)